Cantor Fitzgerald Lowers Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $20.00

Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) had its price target reduced by Cantor Fitzgerald from $23.00 to $20.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Artiva Biotherapeutics' FY2025 earnings at ($2.91) EPS.

ARTV has been the subject of several other research reports. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They set a "buy" rating and a $20.00 target price for the company. Wedbush restated an "outperform" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $20.40.

Artiva Biotherapeutics Stock Down 10.7 %

Shares of NASDAQ ARTV traded down $0.38 during midday trading on Tuesday, reaching $3.16. 80,335 shares of the stock were exchanged, compared to its average volume of 114,168. The company has a 50 day simple moving average of $4.71 and a 200 day simple moving average of $9.23. Artiva Biotherapeutics has a twelve month low of $3.15 and a twelve month high of $17.31.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. RA Capital Management L.P. purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $152,234,000. Franklin Resources Inc. purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $7,435,000. Geode Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $4,774,000. Samsara BioCapital LLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at about $4,506,000. Finally, Wellington Management Group LLP purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.